Dual Chromatin and Cytoskeletal Remodeling by SETD2

Cell

Volumn 166, Issue 4, 2016, Pages 950-962

  Park, In Young ^a,h   Powell, Reid T ^a,h   Tripathi, Durga Nand ^a,h   Dere, Ruhee ^a,h   Ho, Thai H ^b   Blasius, T Lynne ^c   Chiang, Yun Chen ^d   Davis, Ian J ^d   Fahey, Catherine C ^d   Hacker, Kathryn E ^d   Verhey, Kristen J ^c   Bedford, Mark T ^e   Jonasch, Eric ^f   Rathmell, W Kimryn ^d,g   Walker, Cheryl Lyn ^a,h  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; HISTONE METHYLTRANSFERASE; SET DOMAIN CONTAINING 2; UNCLASSIFIED DRUG; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; LYSINE; SET2 PROTEIN, HUMAN; TUBULIN;

ARTICLE; CHROMATIN; CONTROLLED STUDY; CYTOKINESIS; CYTOSKELETON; GENOMIC INSTABILITY; HISTONE ACETYLATION; HISTONE CODE; HISTONE METHYLATION; HUMAN; HUMAN CELL; MICRONUCLEUS; MICROTUBULE; MITOSIS; MITOSIS SPINDLE; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROCESSING; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENETICS; METABOLISM; METHYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYTOKINESIS; CYTOSKELETON; GENOMIC INSTABILITY; HISTONE CODE; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LYSINE; METHYLATION; MICROTUBULES; MITOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUBULIN;

EID: 84981313540     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.07.005     Document Type: Article

References (51)

1. Agromayor, M., Martin-Serrano, J., Knowing when to cut and run: mechanisms that control cytokinetic abscission. Trends Cell Biol. 23 (2013), 433–441.
2. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium, ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
3. Aymard, F., Bugler, B., Schmidt, C.K., Guillou, E., Caron, P., Briois, S., Iacovoni, J.S., Daburon, V., Miller, K.M., Jackson, S.P., Legube, G., Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks. Nat. Struct. Mol. Biol. 21 (2014), 366–374.
4. Barisic, M., Silva e Sousa, R., Tripathy, S.K., Magiera, M.M., Zaytsev, A.V., Pereira, A.L., Janke, C., Grishchuk, E.L., Maiato, H., Mitosis. Microtubule detyrosination guides chromosomes during mitosis. Science 348 (2015), 799–803.
5. Bi, M., Zhao, S., Said, J.W., Merino, M.J., Adeniran, A.J., Xie, Z., Nawaf, C.B., Choi, J., Belldegrun, A.S., Pantuck, A.J., et al. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc. Natl. Acad. Sci. USA 113 (2016), 2170–2175.
6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 (2013), 43–49.
7. Carvalho, S., Vítor, A.C., Sridhara, S.C., Martins, F.B., Raposo, A.C., Desterro, J.M., Ferreira, J., de Almeida, S.F., SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. eLife, 3, 2014, e02482.
8. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
9. Chen, Z., Zang, J., Kappler, J., Hong, X., Crawford, F., Wang, Q., Lan, F., Jiang, C., Whetstine, J., Dai, S., et al. Structural basis of the recognition of a methylated histone tail by JMJD2A. Proc. Natl. Acad. Sci. USA 104 (2007), 10818–10823.
10. Edmunds, J.W., Mahadevan, L.C., Clayton, A.L., Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 27 (2008), 406–420.
11. Fontebasso, A.M., Schwartzentruber, J., Khuong-Quang, D.A., Liu, X.Y., Sturm, D., Korshunov, A., Jones, D.T., Witt, H., Kool, M., Albrecht, S., et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 125 (2013), 659–669.
12. Ganem, N.J., Pellman, D., Limiting the proliferation of polyploid cells. Cell 131 (2007), 437–440.
13. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6, 2013, pl1.
14. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
15. Green, R.A., Paluch, E., Oegema, K., Cytokinesis in animal cells. Annu. Rev. Cell Dev. Biol. 28 (2012), 29–58.
16. Guo, A., Gu, H., Zhou, J., Mulhern, D., Wang, Y., Lee, K.A., Yang, V., Aguiar, M., Kornhauser, J., Jia, X., et al. Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol. Cell. Proteomics 13 (2014), 372–387.
17. Hakimi, A.A., Ostrovnaya, I., Reva, B., Schultz, N., Chen, Y.B., Gonen, M., Liu, H., Takeda, S., Voss, M.H., Tickoo, S.K., et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19 (2013), 3259–3267.
18. Ho, T.H., Kapur, P., Joseph, R.W., Serie, D.J., Eckel-Passow, J.E., Tong, P., Wang, J., Castle, E.P., Stanton, M.L., Cheville, J.C., et al. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod. Pathol. 29 (2016), 34–42.
19. Ho, T.H., Park, I.Y., Zhao, H., Tong, P., Champion, M.D., Yan, H., Monzon, F.A., Hoang, A., Tamboli, P., Parker, A.S., et al. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. Oncogene 35 (2016), 1565–1574.
20. Hu, M., Sun, X.J., Zhang, Y.L., Kuang, Y., Hu, C.Q., Wu, W.L., Shen, S.H., Du, T.T., Li, H., He, F., et al. Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling. Proc. Natl. Acad. Sci. USA 107 (2010), 2956–2961.
21. Huang, K.K., McPherson, J.R., Tay, S.T., Das, K., Tan, I.B., Ng, C.C., Chia, N.Y., Zhang, S.L., Myint, S.S., Hu, L., et al. SETD2 histone modifier loss in aggressive GI stromal tumours. Gut, 2015, 10.1136/gutjnl-2015-309482 Published online September 3, 2015.
22. Huether, R., Dong, L., Chen, X., Wu, G., Parker, M., Wei, L., Ma, J., Edmonson, M.N., Hedlund, E.K., Rusch, M.C., et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat. Commun., 5, 2014, 3630.
23. Janke, C., The tubulin code: molecular components, readout mechanisms, and functions. J. Cell Biol. 206 (2014), 461–472.
24. Jenuwein, T., Allis, C.D., Translating the histone code. Science 293 (2001), 1074–1080.
25. Kanu, N., Grönroos, E., Martinez, P., Burrell, R.A., Yi Goh, X., Bartkova, J., Maya-Mendoza, A., Mistrík, M., Rowan, A.J., Patel, H., et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 34 (2015), 5699–5708.
26. Kizer, K.O., Phatnani, H.P., Shibata, Y., Hall, H., Greenleaf, A.L., Strahl, B.D., A novel domain in Set2 mediates RNA polymerase II interaction and couples histone H3 K36 methylation with transcript elongation. Mol. Cell. Biol. 25 (2005), 3305–3316.
27. Kovac, M., Navas, C., Horswell, S., Salm, M., Bardella, C., Rowan, A., Stares, M., Castro-Giner, F., Fisher, R., de Bruin, E.C., et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat. Commun., 6, 2015, 6336.
28. Kwok, B.H., Kapoor, T.M., Microtubule flux: drivers wanted. Curr. Opin. Cell Biol. 19 (2007), 36–42.
29. Latham, J.A., Dent, S.Y., Cross-regulation of histone modifications. Nat. Struct. Mol. Biol. 14 (2007), 1017–1024.
30. Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
31. Lee, J.S., Smith, E., Shilatifard, A., The language of histone crosstalk. Cell 142 (2010), 682–685.
32. Li, F., Mao, G., Tong, D., Huang, J., Gu, L., Yang, W., Li, G.M., The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell 153 (2013), 590–600.
33. Liao, L., Testa, J.R., Yang, H., The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet. 208 (2015), 206–214.
34. Liu, W., Fu, Q., An, H., Chang, Y., Zhang, W., Zhu, Y., Xu, L., Xu, J., Decreased expression of SETD2 predicts unfavorable prognosis in patients with nonmetastatic clear-cell renal cell carcinoma. Medicine (Baltimore), 94, 2015, e2004.
35. Magiera, M.M., Janke, C., Investigating tubulin posttranslational modifications with specific antibodies. Methods Cell Biol. 115 (2013), 247–267.
36. Mar, B.G., Bullinger, L.B., McLean, K.M., Grauman, P.V., Harris, M.H., Stevenson, K., Neuberg, D.S., Sinha, A.U., Sallan, S.E., Silverman, L.B., et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun., 5, 2014, 3469.
37. Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin-Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 21 (2002), 6820–6831.
38. Motulsky, H.J. (2016) GraphPad Statistics Guide. Accessed 30 May 2016. http://www.graphpad.com/guides/prism/7/statistics/index.htm (GraphPad Software, Inc.).
39. Nelson, C.J., Santos-Rosa, H., Kouzarides, T., Proline isomerization of histone H3 regulates lysine methylation and gene expression. Cell 126 (2006), 905–916.
40. Perdiz, D., Mackeh, R., Poüs, C., Baillet, A., The ins and outs of tubulin acetylation: more than just a post-translational modification?. Cell. Signal. 23 (2011), 763–771.
41. Pfister, S.X., Ahrabi, S., Zalmas, L.P., Sarkar, S., Aymard, F., Bachrati, C.Z., Helleday, T., Legube, G., La Thangue, N.B., Porter, A.C., Humphrey, T.C., SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep. 7 (2014), 2006–2018.
42. Rebehmed, J., Revy, P., Faure, G., de Villartay, J.P., Callebaut, I., Expanding the SRI domain family: a common scaffold for binding the phosphorylated C-terminal domain of RNA polymerase II. FEBS Lett. 588 (2014), 4431–4437.
43. Simon, J.M., Hacker, K.E., Singh, D., Brannon, A.R., Parker, J.S., Weiser, M., Ho, T.H., Kuan, P.F., Jonasch, E., Furey, T.S., et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res. 24 (2014), 241–250.
44. Song, Y., Brady, S.T., Post-translational modifications of tubulin: pathways to functional diversity of microtubules. Trends Cell Biol. 25 (2015), 125–136.
45. Strahl, B.D., Allis, C.D., The language of covalent histone modifications. Nature 403 (2000), 41–45.
46. Verhey, K.J., Gaertig, J., The tubulin code. Cell Cycle 6 (2007), 2152–2160.
47. Wagner, E.J., Carpenter, P.B., Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell Biol. 13 (2012), 115–126.
48. Walczak, C.E., Heald, R., Mechanisms of mitotic spindle assembly and function. Int. Rev. Cytol. 265 (2008), 111–158.
49. Yuan, W., Xie, J., Long, C., Erdjument-Bromage, H., Ding, X., Zheng, Y., Tempst, P., Chen, S., Zhu, B., Reinberg, D., Heterogeneous nuclear ribonucleoprotein L is a subunit of human KMT3a/Set2 complex required for H3 Lys-36 trimethylation activity in vivo. J. Biol. Chem. 284 (2009), 15701–15707.
50. Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481 (2012), 157–163.
51. Zhu, X., He, F., Zeng, H., Ling, S., Chen, A., Wang, Y., Yan, X., Wei, W., Pang, Y., Cheng, H., et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat. Genet. 46 (2014), 287–293.